ZHONGSHENGYAOYE(002317)2025-01-24 10:00Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 220 million and 270 million yuan for the fiscal year 2024, compared to a profit of 263.27 million yuan in the same period last year [4]. - The net profit after deducting non-recurring gains and losses is anticipated to be a loss of between 170 million and 220 million yuan, down from a profit of 304.78 million yuan in the previous year [4]. - The basic earnings per share are projected to be a loss of between 0.26 yuan and 0.32 yuan, compared to earnings of 0.32 yuan per share last year [4]. Product and Market Challenges - The company's core product, the Compound Thrombus Tong series, faced price reductions due to centralized procurement, leading to short-term performance pressure [6]. - Non-recurring gains and losses are expected to reduce net profit by 40 million to 65 million yuan, primarily due to litigation with Shanghai Woli Biotechnology Co., Ltd. [6]. Impairment and R&D Decisions - The company plans to recognize impairment losses on goodwill for its subsidiaries due to long-term sales performance challenges [7]. - The company has decided to temporarily suspend R&D investments in certain oncology drugs based on resource allocation and project viability [7]. - The company anticipates impairment losses on intangible assets related to the drug Liraglutide [8]. Financial Reporting and Disclosure - The financial data presented is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the 2024 annual report [9]. - The company emphasizes the importance of timely information disclosure to mitigate investment risks for shareholders [9].